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Abstract
Background: More information is needed about time between sexual initiation and human papillomavirus (HPV)
infection and development of cervical precancer.
Methods: The objectives were to investigate the time between first sexual activity and detection of first cervical
HPV infection or development of first cervical intraepithelial neoplasia (CIN), and associated factors in women from
the double-blind, multinational, 4-year PATRICIA trial. PATRICIA enroled women aged 15–25 years with no more
than 6 lifetime sexual partners. Women were randomized 1:1 to the HPV-16/18 AS04-adjuvanted vaccine or to
control, but only women from the control arm who began sexual intercourse during the study or within 6 months
before enrolment, and had no HPV infection detected before the recorded date of their first sexual intercourse,
were included in the present analysis. The time between onset of sexual activity and detection of the first cervical HPV
infection or development of the first CIN lesion was analyzed using Kaplan-Meier and univariate and multivariable
Cox proportional-hazards models.
Results: A total of 9337 women were enroled in the control arm of PATRICIA of whom 982 fulfilled the required
inclusion criteria for analysis. A cumulative total of 28%, 44%, and 62% of the subjects had HPV infection within 12, 24,
and 48 months, respectively. The overall incidence rate was 27.08 per 100 person-years. The most common oncogenic
types associated with 6-month persistent infection were HPV-16 (incidence rate: 2.74 per 100 person-years), HPV-51
(2.70), HPV-52 (1.66), HPV-66 (1.14), and HPV-18 (1.09). Increased infection risk was associated with more lifetime sexual
partners, being single, Chlamydia trachomatis history, and duration of hormone use. CIN1+ and CIN2+ lesions were most
commonly associated with HPV-16, with an overall incidence rate of 1.87 and 1.07 per 100 person-years, respectively.
Previous cervical HPV infection was most strongly associated with CIN development.
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Conclusions: More than 25% of women were infected with HPV within 1 year of beginning sexual activity. Without
underestimating the value of vaccination at older ages, our findings emphasize its importance before sexual initiation.
Trial registration: clinicaltrials.gov: NCT00122681.
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Background
Human papillomavirus (HPV), the causal agent of cer-
vical cancer, is believed to be the most common sexu-
ally transmitted infection worldwide, with up to 75% of
sexually active people being infected during their life
[1]. A persistent infection with an oncogenic HPV type
is almost always required before development of cer-
vical pre-cancer or cancer [2-4]. Fortunately, most HPV
infections are transient and clear naturally within a few
months [5]. Individual immune responses are important
in determining the path of an infection, and a limited
number of other non-viral determinants with modest
risks for HPV infection and progression have been well
established [6-11].
HPV vaccination programs have been introduced in
many countries worldwide and are primarily targeted at
adolescent girls. Vaccination before first sexual inter-
course is important because HPV infection is frequently
detected in sexually active adolescent girls and young
women [12,13]. HPV infection often occurs shortly
after onset of sexual activity, and many girls and
women acquire an infection with their first sexual rela-
tionship [13-16].
To add to the body of knowledge concerning the natural
history of HPV, more data are needed about the time be-
tween onset of sexual activity and first acquisition of HPV
infection and first development of detectable lesions under
surveillance using defined referral algorithms. However,
few prospective data are available [13,15,16]. The control
arms of large trials of prophylactic HPV vaccines are well
placed to inform such questions, with large samples of
women with relatively diverse behavioral characteristics,
and data collected on acquisition of different HPV types,
development of pre-cancerous lesions, and factors poten-
tially influencing infection and progression to the first pre-
cancerous lesion.
We have previously reported an analysis of the risk of
progression from cervical HPV infection to pre-cancerous
lesions or clearance of infection from the PApilloma TRial
against Cancer In young Adults (PATRICIA), a phase III
trial of the HPV-16/18 AS04-adjuvanted vaccine (Cervarix®)
in over 18,000 young women [17]. Here, we report an ana-
lysis of the time between first sexual intercourse and acqui-
sition of the first cervical HPV infection or development of
the first pre-cancerous lesion.
Methods
This analysis was based on data obtained from the con-
trol arm of the double-blind, randomized, multinational
(14 countries), controlled, 4-year PATRICIA trial which
enrolled women aged 15–25 years. The objectives were
to investigate the time between first sexual activity and
either detection of the first cervical HPV infection or
development of the first cervical intraepithelial neoplasia
(CIN), and associated factors.
Study population and procedures
The PATRICIA trial design has been described previ-
ously [18,19]. Written informed consent to participate in
the clinical trial was obtained from all adult participants;
for minors, written informed consent was obtained from
their parents or guardians and assent from the partici-
pants themselves.The protocol and other materials were
approved by local independent ethics committees or in-
stitutional review boards (Additional file 1). The clinical
trial was carried out in accordance with The Code of
Ethics of the World Medical Association (Declaration of
Helsinki) and is registered at ClinicalTrials.gov under
number NCT00122681.
PATRICIA enrolled women with no more than 6 life-
time sexual partners. The exclusion criterion of no more
than six lifetime sexual partners was not applied in
Finland, in accordance with local regulatory and ethical
requirements, so women with more than six lifetime
sexual partners enrolled in Finland were included in the
trial [20]. The analysis was based on women from the
control arm of the total vaccinated cohort for efficacy
(TVC-E) which included all women who received at
least one dose of control vaccine and had normal or low
grade cytology at baseline. The present analysis included
women who began sexual intercourse either during the
follow-up period or less than 6 months before enrol-
ment. Women beginning sexual intercourse during the
study must not have had HPV infection detected before
the first recorded date of sexual intercourse. However,
women who began sexual intercourse within 6 months
before enrolment were included regardless of whether
they had a prevalent HPV infection at baseline or not.
HPV genotyping of cervical liquid-based cytology sam-
ples by polymerase chain reaction (PCR) was done at
baseline and every 6 months. The Bethesda system was
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used for cytologic classification approximately every
12 months, with histologic classification of any biopsies.
We tested for the following oncogenic HPV types: HPV-
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68,
and for the following non-oncogenic types: HPV-6, 11,
34, 40, 42, 43, 44, 53, 54, 70, and 74 [21].
A self-administered behavioral questionnaire collect-
ing data on smoking, sexual activity, and contraception
was completed 1 month after first vaccination and yearly
thereafter during the follow-up period [22]. Participants were
informed that the term sexual intercourse included penetra-
tive, genital-to-genital, or oral-genital sexual contact.
Endpoint definitions
The first HPV infection detected or first CIN detected
was used in the analysis. HPV infections were classified
as an infection of any duration (HPVI) and as a 6-month
persistent infection (6MPI). A 6MPI was defined as de-
tection of the same HPV genotype in cervical samples at
two consecutive evaluations over approximately a 6-
month period i.e. a sequence of positive samples with
the same HPV type not interrupted by negative samples
over a total range of >5 months (>150 days). The start of
the 6MPI was defined as the date of the first positive
sample in the sequence. Histopathologically confirmed
CIN was detected in biopsy samples after colposcopy or
excision samples after treatment. Endpoints were defined
as CIN grade 1 or greater (CIN1+) and CIN grade 2 or
greater (CIN2+). Only HPV-positive lesions were in-
cluded in the analysis.
Statistical analysis
Incidence rates for HPVI, 6MPI and CIN were calculated
per 100 person-years (PY) according to individual HPV
type, with 95% confidence intervals (CI). The time to de-
tection of the first cervical HPV infection or development
of the first CIN lesion was measured from the date of first
sexual intercourse reported by the woman. Thus, although
visits were scheduled for every 6 months, it was possible
to establish a duration of infection of less than 6 months.
The time between onset of sexual activity and detection of
the first infection or CIN lesion was analysed using the
Kaplan-Meier method as well as univariate and multivari-
able Cox proportional-hazards models. The statistical unit
was the subject.
Nine potential factors (covariates) associated with acqui-
sition of HPV infection were included in the models:
region, tobacco exposure measured as number of pack-
years (one pack-year was equivalent to 365 packs of ciga-
rettes), age at first sexual intercourse (15–17 years and ≥
18 years), number of sexual partners during the past
12 months, number of lifetime sexual partners, history of
Chlamydia trachomatis during the past 12 months, mari-
tal/partner status, use of hormones for contraception or
other indication, and duration of use of hormones for
contraception or other indication. The number of life-
time sexual partners was determined from the behav-
ioral questionnaire. All behavioural covariates were
considered as time dependent and therefore no propor-
tional hazard checks were required. Region and age
were considered as time-fixed covariates and the hazard
assumptions were assessed directly from the Kaplan-
Meier curves. In addition, for the time to detection of a
6MPI, CIN1+ and CIN2+, the models also included
previous cervical HPV infection as a time-varying co-
variate. Previous cervical HPV infection was defined as
an HPV infection preceding the onset of the referent
6MPI or preceding the onset of the referent infection
associated with a CIN1+ or CIN2 +.
Data were censored for women who completed the
study at 54 months after first sexual intercourse (although
follow-up lasted for 48 months, women were included in
the analysis if they had their first sexual experience within
6 months before enrolment). For women who did not
complete the study, data were censored at their last
recorded visit. Covariates with a p-value <0.2 in the uni-
variate model were included in the multivariable models,
with the exception of region which was always included
regardless of the p-value obtained. All analyses were
performed using SAS version 9.2.
Results
Subject disposition and characteristics
A total of 982 women who experienced first sexual inter-
course during the study and had no HPV infection de-
tected before the recorded date of their first experience of
sexual intercourse, and women who experienced first sex-
ual intercourse less than 6 months before inclusion, were
included in the analysis (Figure 1). Among these 982
women, mean age was 17.4 years (standard deviation 2.13),
and most were from Europe (65.6%, with 60.8% from
Finland), followed by Asia-Pacific (17.1%), North America
(9.6%) and Latin America (7.7%). Most women included in
the present analysis had not experienced sexual intercourse
before study entry (n = 793, 80.8%), 169 women (17.2%)
had experienced first sexual intercourse within 6 months
prior to study entry, and data on sexual history were miss-
ing for 20 women (2.0%). Eight (4.7%) and nine (5.3%) of
the women who experienced first sexual intercourse prior
to study entry were seropositive for HPV-16 or HPV-18,
respectively, at study entry.
First cervical HPV infection of any duration and 6-month
persistent infection: incidence and association of
covariates
An HPVI was detected in 496 women (50.5%; 27.08 per
100 person-years) (Table 1). No HPVI had been detected
by the end of the follow-up period in 446 women
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(45.4%) who completed the study, and no HPVI had been
detected by the time of their last visit in 40 women (4.1%)
who discontinued before the end of the study. Corre-
sponding values for 6MPI were 281 (28.6%; 13.29 per 100
person-years), 648 (66.0%) and 53 (5.4%). The first cases
of HPV infections were detected within 2–3 months after
sexual initiation and the cumulative number of women
with an infection increased progressively throughout
follow-up for both HPVI and 6MPI (Figure 2a and b). The
cumulative percentage of women infected with any HPV
type at 12, 18, 24, 36 and 48 months was 28%, 36%, 44%,
53% and 62%, respectively (Figure 2a).
Among oncogenic HPV types, the most commonly de-
tected HPVIs were HPV-51 (5.95 per 100 PY), HPV-16
(4.91 per 100 PY), HPV-52 (3.33 per 100 PY), HPV-18
(2.73 per 100 PY), and HPV-66 (2.51 per 100 PY)
(Table 1). These types were also the most commonly
detected 6MPIs, although HPV-18 was slightly less com-
mon than HPV-66 (Table 1). HPV-6 and HPV-53 were the
most common non-oncogenic HPV types detected in
HPVI (4.04 and 3.06 per 100 PY, respectively) and 6MPI
(0.99 and 1.32 per 100 PY, respectively) (Table 1). The
incidence of infection with at least one oncogenic HPV
type was considerably higher than the incidence of infec-
tion with only non-oncogenic types: 21.79 versus 5.30 per
100 PY, respectively, for HPVI, and 10.97 versus 2.32 per
100 PY, respectively, for 6MPI (Table 1; Figure 2a and b).
In the multivariable analysis, the main covariate associ-
ated with increased risk of acquiring an HPVI was a higher
number of lifetime sexual partners. The hazard ratio [HR]
was 4.76 (95% CI: 3.82–5.95) and 19.22 (14.02–26.34) for
2–3 partners and ≥4 partners, respectively (Table 2). Other
covariates significantly associated with increased risk were
history of infection with Chlamydia trachomatis (HR:
3.00 [2.07–4.36]) and cumulative duration of hormone
use (HR: 2.18 [1.68–2.83] for 1–12 months, 3.26
[2.45–4.34] for 13–48 months and 5.42 [2.84–10.36]
for >48 months). Being a single woman was signifi-
cantly associated with an increased risk of acquiring an
HPVI (HR: 1.45 [1.04–2.04]) compared with living with
a partner currently or in the past. Tobacco exposure
did not increase the risk in the multivariable analysis,
although it was significant in the univariate analysis
(HR: 1.66 [1.33–2.08], p < 0.0001).
Figure 1 Subject disposition.
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The same covariates were significantly associated with
higher risk of a 6MPI in the multivariable analysis, with
the exception of hormone use for >48 months (Table 2).
Being single was again significantly associated with
higher risk of a 6MPI (HR: 1.75 [1.01–3.03]); previous
cervical HPV infection was associated with lower risk
(HR: 0.49 [0.33–0.72]) (Table 2).
First cervical intraepithelial neoplasia grade 1 or greater
and cervical intraepithelial neoplasia grade 2 or greater:
incidence and association of covariates
Few cases of CIN1+ or CIN2+ were observed. A CIN1+
was detected in 50 women (5.1%; 1.87 per 100 person-
years) (Table 1). No CIN1+ had been detected by the
end of the follow-up period in 866 women (88.2%) who
Table 1 Incidence of first cervical HPVI, 6MPI, CIN1+ and CIN2+
HPV type HPVI (N = 496) 6MPI (N = 281) CIN1+ (N = 50) CIN2+ (N = 29)
n (%) Incidence per
100 PY (95% CI)1
n (%) Incidence per
100 PY (95% CI)1
n (%) Incidence per
100 PY (95% CI)1
n (%) Incidence per
100 PY (95% CI)1
All 496 (50.5)2 27.08 (24.75-29.57) 281 (28.6)2 13.29 (11.78-14.94) 50 (5.1)2 1.87 (1.39-2.46) 29 (3.0)2 1.07 (0.72-1.54)
Oncogenic HPV types
16 90 (18.2) 4.91 (3.95-6.04) 58 (20.6) 2.74 (2.08-3.55) 22 (44.0) 0.82 (0.52-1.24) 17 (58.6) 0.63 (0.37-1.01)
18 50 (10.1) 2.73 (2.03-3.60) 23 (8.2) 1.09 (0.69-1.63) 3 (6.0) 0.11 (0.02-0.33) 2 (6.9) 0.07 (0.01-0.27)
31 32 (6.5) 1.75 (1.20-2.47) 19 (6.8) 0.90 (0.54-1.40) 6 (12.0) 0.22 (0.08-0.49) 2 (6.9) 0.07 (0.01-0.27)
33 21 (4.2) 1.15 (0.71-1.75) 10 (3.6) 0.47 (0.23-0.87) 4 (8.0) 0.15 (0.04-0.38) 3 (10.3) 0.11 (0.02-0.32)
35 9 (1.8) 0.49 (0.22-0.93) 3 (1.1) 0.14 (0.03-0.41) 1 (2.0) 0.04 (0.00-0.21) 0 0.00 (0.00-0.14)
39 34 (6.9) 1.86 (1.29-2.59) 20 (7.1) 0.95 (0.58-1.46) 3 (6.0) 0.11 (0.02-0.33) 2 (6.9) 0.07 (0.01-0.27)
45 22 (4.4) 1.20 (0.75-1.82) 6 (2.1) 0.28 (0.10-0.62) 1 (2.0) 0.04 (0.00-0.21) 0 0.00 (0.00-0.14)
51 109 (22.0) 5.95 (4.89-7.18) 57 (20.3) 2.70 (2.04-3.49) 7 (14.0) 0.26 (0.11-0.54) 4 (13.8) 0.15 (0.04-0.38)
52 61 (12.3) 3.33 (2.55-4.28) 35 (12.5) 1.66 (1.15-2.30) 4 (8.0) 0.15 (0.04-0.38) 2 (6.9) 0.07 (0.01-0.27)
56 44 (8.9) 2.40 (1.75-3.23) 19 (6.8) 0.90 (0.54-1.40) 5 (10.0) 0.19 (0.06-0.44) 3 (10.3) 0.11 (0.02-0.32)
58 22 (4.4) 1.20 (0.75-1.82) 14 (5.0) 0.66 (0.36-1.11) 7 (14.0) 0.26 (0.11-0.54) 2 (6.9) 0.07 (0.01-0.27)
59 26 (5.2) 1.42 (0.93-2.08) 1 (0.4) 0.05 (0.00-0.26) 0 0.00 (0.00-0.14) 0 0.00 (0.00-0.14)
66 46 (9.3) 2.51 (1.84-3.35) 24 (8.5) 1.14 (0.73-1.69) 4 (8.0) 0.15 (0.04-0.38) 1 (3.5) 0.04 (0.00-0.21)
68 37 (7.5) 2.02 (1.42-2.78) 17 (6.1) 0.80 (0.47-1.29) 4 (8.0) 0.15 (0.04-0.38) 3 (10.3) 0.11 (0.02-0.32)
At least 1 oncogenic
type
399 (80.4) 21.79 (19.70-24.03) 232 (82.6) 10.97 (9.61-12.48) 50 (100.0) 1.87 (1.39-2.46) 29 (100) 1.07 (0.72-1.54)
Non-oncogenic HPV types
6 74 (14.9) 4.04 (3.17-5.07) 21 (7.5) 0.99 (0.61-1.52) 3 (6.0) 0.11 (0.02-0.33) 1 (3.5) 0.04 (0.00-0.21)
11 9 (1.8) 0.49 (0.22-0.93) 1 (0.4) 0.05 (0.00-0.26) 2 (4.0) 0.07 (0.01-0.27) 0 0.00 (0.00-0.14)
34 7 (1.4) 0.38 (0.15-0.79) 1 (0.4) 0.05 (0.00-0.26) 0 0.00 (0.00-0.14) 0 0.00 (0.00-0.14)
40 16 (3.2) 0.87 (0.50-1.42) 1 (0.4) 0.05 (0.00-0.26) 2 (4.0) 0.07 (0.01-0.27) 1 (3.5) 0.04 (0.00-0.21)
42 7 (1.4) 0.38 (0.15-0.79) 0 0.00 (0.00-0.17) 0 0.00 (0.00-0.14) 0 0.00 (0.00-0.14)
43 27 (5.4) 1.47 (0.97-2.14) 3 (1.1) 0.14 (0.03-0.41) 0 0.00 (0.00-0.14) 0 0.00 (0.00-0.14)
44 4 (0.8) 0.22 (0.06-0.56) 1 (0.4) 0.05 (0.00-0.26) 0 0.00 (0.00-0.14) 0 0.00 (0.00-0.14)
53 56 (11.3) 3.06 (2.31-3.97) 28 (10.0) 1.32 (0.88-1.91) 3 (6.0) 0.11 (0.02-0.33) 2 (6.9) 0.07 (0.01-0.27)
54 16 (3.2) 0.87 (0.50-1.42) 8 (2.9) 0.38 (0.16-0.75) 3 (6.0) 0.11 (0.02-0.33) 2 (6.9) 0.07 (0.01-0.27)
70 6 (1.2) 0.33 (0.12-0.71) 6 (2.1) 0.28 (0.10-0.62) 1 (2.0) 0.04 (0.00-0.21) 0 0.00 (0.00-0.14)
74 13 (2.6) 0.71 (0.38-1.21) 6 (2.1) 0.28 (0.10-0.62) 0 0.00 (0.00-0.14) 0 0.00 (0.00-0.14)
Only non-oncogenic
type
97 (19.6) 5.30 (4.29-6.46) 49 (17.4) 2.32 (1.71-3.06) 0 0.00 (0.00-0.14) 0 0.00 (0.00-0.14)
1Number of person-years: 1831.46 (HPVI); 2114.51 (6MPI); 2676.71 (CIN1+); 2703.47 (CIN2+).
2 N = 982.
Some women experienced concomitant HPV infections, concomitant CIN lesions and/or CIN lesions associated with more than 1 HPV type. Therefore the number
of observations for each individual HPV type do not add up to the total number of women experiencing an infection or lesion (N).
6MPI: 6-month persistent HPV infection; CI: confidence interval; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; HPVI: HPV infection of any duration;
PY: person-years.
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completed the study, and no CIN1+ had been detected
by the time of their last visit in 66 women (6.7%) who
discontinued before the end of the study. Corresponding
values for CIN2+ were 29 (3.0%; 1.07 per 100 person-
years), 886 (90.2%) and 67 (6.8%). The first cases of
CIN1+ lesions were detected approximately 6 months
following sexual initiation. The cumulative proportion of
women developing a CIN1+ lesion was 3% at 24 months
and 10% at 48 months (Figure 2c). The first cases of
CIN2+ lesions were detected within approximately 12–18
months after sexual initiation; the cumulative proportion
of women developing a CIN2+ lesion was 1% at 24 months
and 6% at 48 months (Figure 2d). CIN lesions were most
commonly associated with HPV-16 (Table 1; Figure 2c
and d). Other oncogenic HPV types most often detected
in a CIN lesion were HPV-51, HPV-58, and HPV-31. No
lesions associated only with non-oncogenic HPV types
were found (Table 1).
The covariate most strongly associated with in-
creased risk of CIN1+ in the multivariable analysis was
previous cervical HPV infection (HR: 35.70 [95% CI:
8.47–150.50]) (Table 3). Having ≥4 lifetime sexual
partners was also significantly associated with increased
risk (HR: 5.60 [2.28–13.77]). Cumulative duration of
hormone use was associated with higher risk, but just
failed to achieve statistical significance (HR: 3.61
[0.94–13.86], 3.84 [1.00–14.77] and 6.09 [0.89–41.63]
for 1–12, 13–48 and >48 months, respectively). Being
from the Asia-Pacific region was significantly associated
with increased risk (HR: 2.99 [1.03–8.70]), although it
should be noted that only six women from this region
experienced CIN1 +.
Previous cervical HPV infection also had the greatest
influence on risk of developing CIN2+, with a HR of
42.30 (5.61–318.63), and having ≥4 lifetime sexual
partners was also associated with higher risk (HR: 4.02
[1.24–13.05]) (Table 3). Age 15–17 years at first sexual
intercourse was significantly associated with lower risk
of developing CIN2+ compared with age ≥18 years;
however, only 3 women with first experience of sexual
intercourse at age 15–17 years experienced a CIN2 +.
A sensitivity analysis not including the factor of previous
infection in the model did not change the HR for the other
covariates for CIN1+ and CIN2+ (data not shown). Like-
wise, a sensitivity analysis of all lesions (including both
HPV-positive and HPV-negative cases) revealed similar
results except for CIN2+ where the cumulative duration of
hormone use had a univariate p-value <0.2 and was
thus included in the multivariable analysis (whereas
it was not included in the multivariable analysis of
Figure 2 Risk of developing a first cervical HPV infection or lesion following first sexual intercourse. a. HPVI. b. 6MPI. c. CIN1+. d. CIN2+.
Any oncogenic HPV type: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
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Table 2 Factors associated with risk of the first cervical HPVI or 6MPI (multivariable Cox proportional-hazards analysis)
Covariate Category HPVI 6MPI
No. of women
(N = 982)
No. of women with
HPVI (N = 496) HR (95% CI)
p-value No. of women
(N = 982)
No. of women with
6MPI (N = 281)
HR (95% CI) p-value
Region Europe 644 345 1 644 201 1
Asia Pacific 168 58 1.11 (0.81-1.52) 0.5055 168 36 1.21 (0.78-1.86) 0.3995
Latin America 76 46 1.16 (0.84-1.60) 0.3627 76 24 0.99 (0.63-1.57) 0.9773
North America 94 47 0.88 (0.64-1.20) 0.4273 94 20 0.75 (0.47-1.20) 0.2283
0.5498 0.4934
Number of lifetime sexual partners1 1 800 234 1 800 127 1
2-3 430 190 4.76 (3.82-5.95) <0.0001 470 111 4.19 (3.12-5.63) <0.0001
≥4 125 72 19.22 (14.02-26.34) <0.0001 166 43 14.14 (9.35-21.37) <0.0001
<0.0001 <0.0001
History of Chlamydia trachomatis
during the past 12 months1
No 977 463 1 978 257 1
Yes 60 33 3.00 (2.07-4.36) <0.0001 73 24 2.50 (1.57-4.00) 0.0001
<0.0001 0.0001
Cumulative duration of hormone
use for contraception or other indication1
No use 804 105 1 804 59 1
1-12 months 727 173 2.18 (1.68-2.83) <0.0001 746 111 2.10 (1.48-2.98) <0.0001
13-48 months 536 206 3.26 (2.45-4.34) <0.0001 590 108 2.79 (1.91-4.09) <0.0001
>48 months 56 11 5.42 (2.84-10.36) <0.0001 69 2 1.62 (0.39-6.74) 0.5107
<0.0001 <0.0001
Marital/partner status1 Living or lived
with partner
238 42 1 271 19 1
Single 961 454 1.45 (1.04-2.04) 0.0291 963 262 1.75 (1.01-3.03) 0.0445
0.0291 0.0445
Tobacco exposure (number of pack-years)1 <0.5 862 402 1 862 223 1
≥0.5 153 94 1.17 (0.92-1.47) 0.1936 161 58 1.22 (0.90-1.66) 0.2085
0.1936 0.2085
Previous cervical HPV infection1 No - - - - 965 231 1
Yes - - - - 188 38 0.49 (0.33-0.72) 0.0003
- 0.0003
1Time-varying covariates. The number of women represents the number of observations that appeared at least once during the follow-up period. One woman can be counted in several categories. The number of
events (HPVI or 6MPI) corresponds to the value recorded at the most recent visit before the endpoint.
Values in italics are the overall p-value.
Age at first sexual intercourse was not included in the multivariable analyses because p-values of >0.2 were obtained in the univariate analyses. The covariates of number of sexual partners during the past 12 months
and hormone use or not for contraception or another indication were not included in the multivariable analyses because of overlap with the covariates of number of lifetime sexual partners and cumulative duration
of hormone use or other indication, respectively.
6MPI: 6-month persistent HPV infection; CI: confidence interval; HPV: human papillomavirus; HPVI: HPV infection of any duration; HR: Hazard ratio.
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HPV-positive CIN2+). However, it was not significant in
the multivariable analysis.
Discussion
The analysis confirmed that HPV infection may be ac-
quired relatively quickly following first sexual intercourse.
The first cases of HPV infections were detected within 2–3
months following sexual initiation, and two thirds of
women had acquired an infection within the 48 month
follow-up period. Persistent infections were less common,
detected in approximately one-quarter of women. The first
cases of CIN1+ lesions were detected approximately
6 months following sexual initiation, and the first CIN2+
lesions approximately 12–18 months, but both were expe-
rienced by very few women.
Other studies of virginal women experiencing sexual
intercourse for the first time have shown broadly similar
rates of oncogenic HPV acquisition, although it is difficult
to compare estimates directly because of differences across
studies in outcomes and follow-up times. At 2 years after
sexual initiation, we found an incidence of HPV infection
of 44%. Two previous studies have found slightly lower
incidences at this time point. A population-based cohort
study conducted in Denmark found an incidence of 35%
among 70 women recruited as virgins and experiencing
first sexual intercourse within the follow-up period [15],
whilst a study of 444 HPV DNA-negative female students
from the US (94 recruited as virgins and experiencing first
sexual intercourse within the follow-up period) found an
incidence of 39% for both women who were virgin and
those who were sexually active at enrolment [13]. In the
latter study, the minimum time between first sexual inter-
course and detection of HPV was less than 1 month [13].
Likewise, the incidence of HPV infection at 3 years was
53% in our analysis, slightly higher than the 46% incidence
at the same time point found among 242 women from the
UK recruited within 6 months of first sexual intercourse
and with only one partner [14]. In a study of 206 women
from the Guanacaste cohort recruited as virgins and ex-
periencing first sexual intercourse within the follow-up, the
incidence of cervical HPV infection was 53% after a
median follow-up of 3.6 years [16], compared with an inci-
dence of 62% after 4 years in our analysis.
In our analysis, the most common oncogenic HPV types
in HPVI and 6MPI were HPV-16 and HPV-51, followed
by HPV-52, and then by HPV-18 and HPV-66. HPV-6
was the most common non-oncogenic type; however, its
incidence may be underestimated because the study did
not systematically evaluate the external genital tract. In
the overall PATRICIA cohort, the most common preva-
lent HPV types at study entry were HPV-16, followed by
HPV-51, HPV-18, and HPV-31 [22]. This is in line with
previous studies of the occurrence of different HPV types,
although there is considerable variation between studies
and regions in the exact ranking and incidence of the dif-
ferent types, and 95% confidence intervals of incidence are
broad. In the Guanacaste subcohort of women recruited as
virgins, the most common oncogenic HPV types detected
were HPV-16, HPV-66, and HPV-52; HPV-53 was the
most common non-oncogenic type detected [16]. Amongst
HPV DNA-negative students from the US, the most com-
mon HPV types detected at first infection were HPV-16,
HPV-56, and HPV-6 [13]. A meta-analysis of more than 1
million women worldwide found HPV-16 to be by far the
most common type in women with normal cytology,
followed by HPV-18, HPV-52, HPV-31, and HPV-58 [23].
Few women experienced CIN1+ and even fewer experi-
enced CIN2+, so estimates of time to lesion development
and the most common HPV type associated with CIN
lesions have somewhat low precision. However, it was clear
that HPV-16 was by far the most frequent type found in
CIN1+ and CIN2+, as seen in other studies [24,25].
In our analysis, higher number of lifetime sexual partners
was most strongly associated with a higher risk of an HPVI
or 6MPI. History of Chlamydia trachomatis infection and
longer cumulative duration of hormone use also signifi-
cantly increased the risk of acquisition. Although the uni-
variate analysis indicated an increased risk for HPVI with
tobacco exposure, the multivariable analysis showed no
significant association. For the overall PATRICIA cohort,
infection with HPV at entry was significantly associated
with not being married or living with a partner, tobacco
exposure, age <15 years at first sexual intercourse, higher
number of sexual partners during the past 12 months,
longer duration of hormone use, and history of a sexually
transmitted infection [22]. The PATRICIA findings are in
line with previous studies of risk factors influencing acqui-
sition of HPV infection. In the Danish study of women
experiencing first sexual intercourse mentioned previ-
ously, having ≥3 sexual partners increased the risk of
infection 9-fold; age, smoking habits, oral contraceptive
use, and age at first sexual intercourse were not signifi-
cantly associated with infection [15]. In the US study of
students, current smoking, current oral contraceptive use,
higher number of lifetime sexual partners, male partners’
number of prior sexual partners, and knowing a partner
for less than 8 months before sexual intercourse were
predictors of HPV infection [13].
Previous cervical HPV infection was associated with
lower risk of a 6MPI with any HPV type, perhaps indicating
a protective effect of naturally acquired antibodies to the
prior infection. In contrast, previous cervical HPV infection
was strongly associated with increased risk of developing
CIN1+ and CIN2+. In another analysis of the whole
PATRICIA control group, previous infection with an
oncogenic HPV type was also significantly associated with
increased risk of developing CIN1+ and CIN2+ [17].
Accumulation of HPV infections may indicate that an
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Table 3 Factors associated with risk of the first CIN1+ or CIN2+ (multivariable Cox proportional-hazards analysis)
Covariate Category CIN1+ CIN2+
No. of
women
(N = 982)
No. of women
with CIN1+
(N = 50)
HR (95% CI) p-value No. of
women
(N = 982)
No. of women
with CIN2+
(N = 29)
HR (95% CI) p-value
Region Europe 644 35 1 644 21 1
Asia Pacific 168 6 2.99 (1.03-8.70) 0.0441 168 3 0.76 (0.20-2.93) 0.6942
Latin America 76 3 1.18 (0.34-4.05) 0.7932 76 1 0.57 (0.07-4.37) 0.5869
North
America
94 6 1.93 (0.80-4.68) 0.1439 94 4 1.73 (0.58-5.18) 0.3238
0.1480 0.6452
Age at first sexual intercourse ≥18 years 801 41 1 801 26 1
15-17 years 181 9 0.46 (0.21-1.02) 0.0545 181 3 0.18 (0.05-0.64) 0.0086
0.0545 0.0086
Number of lifetime sexual partners1 1 800 9 1 800 5 1
2-3 537 15 1.73 (0.72-4.15) 0.2213 537 10 1.93 (0.63-5.92) 0.2529
≥4 245 26 5.60 (2.28-13.77) 0.0002 248 14 4.02 (1.24-13.05) 0.0203
0.0001 0.0504
Cumulative duration of hormone use for contraception or other
indication1
No use 804 3 1 Not included
1-12 months 786 13 3.61 (0.94-13.86) 0.0614
13-48 months 707 32 3.84 (1.00-14.77) 0.0502
>48 months 102 2 6.09 (0.89-41.63) 0.0653
0.2157
Tobacco exposure (number of pack-years)1 <0.5 862 36 1 Not included
≥0.5 177 14 1.44 (0.76-2.74) 0.2622
0.2622
Previous cervical HPV infection1 No 974 2 1 975 1 1
Yes 431 48 35.70 (8.47-
150.50)
<0.0001 432 28 42.30 (5.61-
318.63)
0.0003
<0.0001 0.0003
1Time-varying covariates. The number of women represents the number of observations that appeared at least once during the follow-up period. One woman can be counted in several categories. The number of
events (CIN1+ or CIN2+) corresponds to the value recorded at the most recent visit before the endpoint.
Values in italics are the global p-value.
History of Chlamydia trachomatis (CIN1+ and CIN2+), cumulative duration of hormone use (CIN2+), marital/partner status (CIN1+ and CIN2+) and tobacco exposure (CIN2+) were not included in the multivariable
analyses because p-values of >0.2 were obtained in the univariate analyses. The covariates of number of sexual partners during the past 12 months and hormone use or not for contraception or another indication
were not included in the multivariable analyses because of overlap with the covariates of number of lifetime sexual partners and cumulative duration of hormone use or other indication, respectively.
CI: confidence interval; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; HR: hazard ratio.
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individual’s immune system may have limited ability to
clear infections, thus increasing their risk of developing
CIN. In contrast to our findings, some studies have shown
that there is a higher chance of acquiring a new HPV type
if already infected [26-28]. Unfortunately, in the PATRI-
CIA trial, information on HPV serology over time was
only available for a sub-cohort of women, and the number
of women in the control group of the immunogenicity
cohort who had not initiated sexual intercourse at enrolment
was too small for meaningful analysis to explore the role of
serology in the risk of HPV infections and CIN.
Four or more lifetime sexual partners was also associated
with increased risk of CIN1+ and CIN2+. An association
between cervical cancer and higher number of sexual part-
ners has been seen in previous studies [8]. Younger age at
first sexual intercourse was associated with lower risk of
CIN2+; however, as there were only three cases of CIN2+
in the 15–17 year age group, this finding should be inter-
preted cautiously. Younger age at first sexual intercourse
has been previously shown to be associated with increased
risk of cervical cancer [8].
A strength of our analysis is that participants of the
PATRICIA study were well-characterized, with high
follow-up rates over 4 years and standardized virologic
and histologic sampling methods. Although the population
of the present analysis was a relatively small subset of the
entire PATRICIA population, more women were included
in this analysis than in any other study of virginal women.
Study limitations included the fact that women from
Finland made up approximately two thirds of the popula-
tion who had not had experience of sexual intercourse
before enrolment, a consequence of the school-based trial
recruitment strategy in Finland. In addition, PATRICIA
included only women aged 15–25 years with no history of
immunosuppressive disease, limiting its generalizability.
The smaller population in the present analysis meant that
the 4-year follow-up period was long enough to detect only
a small number of CIN cases, limiting the conclusions that
can be drawn about the time between first sexual inter-
course and development of pre-cancerous lesions.
Conclusion
Infection with HPV can occur within 2–3 months follow-
ing first sexual intercourse, and the first CIN1+ lesions
within approximately 6 months. The role of previous
cervical HPV infection in increasing the risk of developing
a pre-cancerous lesion is confirmed, as is the role of the
number of lifetime sexual partners in acquisition of an
HPV infection. Our estimates of time to infection and time
to CIN after sexual initiation are important as they will
inform modeling exercises on the natural history of
cervical carcinogenesis and the impact of HPV vaccination
programs. Furthermore, without underestimating the value
of vaccination at older ages, our findings emphasize the
importance of vaccinating at a young age, well before girls
begin sexual activity, most likely achieved via school-based
vaccination programs.
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